No Picture
News

Halozyme Announces First Clinical Dosing In argenx’s Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology

SAN DIEGO, July 17, 2019 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that argenx has dosed the first subject in a phase 1 clinical trial … […]

No Picture
News

Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155

SAN DIEGO, July 9, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a clinical collaboration agreement with Novartis to evaluate the combination of MRTX849, Mirati’s investiga… […]

No Picture
News

Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology

– NIAID to Study Use of ENHANZE® Technology with Broadly Neutralizing Antibodies for Development of New HIV Treatments –

SAN DIEGO, June 25, 2019 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a Cooperative Research and D… […]

No Picture
News

EpicentRx Announces Publication of Its Positive Phase 2 3rd Line SCLC Results With RRx-001 Plus a Platinum Doublet in the British Journal of Cancer (BJC)

LA JOLLA, Calif., June 25, 2019 /PRNewswire/ — EpicentRx Inc., a clinical-stage immuno-oncology company with two platforms developed to prime and activate both innate and adaptive anticancer responses, today announced the publication of positive r… […]

No Picture
News

Immunic, Inc. Files Financial Statements and Pro Forma Financial Information in Accordance with Previously Completed Stock-for-Stock Exchange Transaction and Provides Corporate Update

– Phase 2 Trial in Relapsing-Remitting Multiple Sclerosis Expected to be the First Efficacy Read-Out of IMU-838; Top-line Data Anticipated in Q3 2020 –

SAN DIEGO, June 21, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmac… […]

No Picture
News

German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score® Test

Reimbursement Decision Follows IQWiG’s Recommendation Based on TAILORx Study Results

REDWOOD CITY, Calif., June 20, 2019 /PRNewswire/ — Genomic Health announced today that the German Federal Joint Committee (G-BA) issued a positive reimbursement dec… […]

No Picture
News

Sophiris Bio Receives Positive Feedback from European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design

Conference call scheduled for today at 9:30 a.m. EDT

SAN DIEGO and VANCOUVER, British Columbia, June 19, 2019 /PRNewswire/ — Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a … […]

No Picture
News

MDA Awards Venture Philanthropy Grant to Locana to Develop Novel Treatment for Muscular Dystrophy

NEW YORK and SAN DIEGO, June 12, 2019 /PRNewswire/ — The Muscular Dystrophy Association (MDA) and Locana, a leading RNA-targeting gene therapy company, today announced the award of an MDA Venture Philanthropy (MVP) grant totaling $550,000 to advan… […]

No Picture
News

Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson’s Disease and Related Disorders

– INGREZZA Data from Long-Term Phase III Studies Support Sustained Clinical Benefit, Safety and Tolerability in Patients with Tardive Dyskinesia- Pooled Analyses of Two Pivotal Studies Showed Opicapone Reduced OFF Time and Was Generally Well Tolerate… […]